Incidence of Severe COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia or Indolent B-cell Non-Hodgkin Lymphoma Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy: an Observational Study by the GIMEMA Working Party on Chronic Lymphoproliferative Disorders and by the Fondazione Italiana Linfomi
Status: Recruiting
Location: See all (15) locations...
Study Type: Observational
SUMMARY
This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who received first COVID-19 prophylaxis dose between March 2022 and October 2022.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years
• Patient with CLL or indolent B-NHL who received the first COVID-19 prophylaxis dose with Tixagevimab and Cilgavimab as per label indication between March 2022 and October 2022.
• Signed informed consent, if applicable
Locations
Other Locations
Italy
UOC Ematologia AO Cosenza
RECRUITING
Cosenza
Ematologia AOU S.Anna
RECRUITING
Ferrara
Ematologia AOU Careggi
RECRUITING
Florence
ASST Lecco Ospedale A.Manzoni
RECRUITING
Lecco
UOC Ematologia ATMO
RECRUITING
Livorno
ASST Grande Ospedale Metropolitano Niguarda
RECRUITING
Milan
SCDU Ematologia
RECRUITING
Novara
Dipartimento Oncologico La Maddalena
RECRUITING
Palermo
UOC DI ONCOEMATOLOGIA AOR Villa Sofia - Cervello
RECRUITING
Palermo
Ematologia Università Sapienza Roma
RECRUITING
Roma
IRCCS Istituto Clinico Humanitas
RECRUITING
Rozzano
UOC Ematologia Casa Sollievo della Sofferenza
RECRUITING
San Giovanni Rotondo
SCDU Ematologia e terapie cellulari AO Mauriziano
RECRUITING
Torino
Ematologia Ospedale S.Chiara
RECRUITING
Trento
UOC ematologia ULSS2 Marca Trevigiana
RECRUITING
Treviso
Contact Information
Primary
Paola Fazi
p.fazi@gimema.it
0670390528
Backup
Enrico Crea
e.crea@gimema.it
0670390514
Time Frame
Start Date: 2023-09-12
Estimated Completion Date: 2024-09
Participants
Target number of participants: 954
Related Therapeutic Areas
Sponsors
Leads: Gruppo Italiano Malattie EMatologiche dell'Adulto
Collaborators: Fondazione Italiana Linfomi